Gankyrin inhibits ferroptosis through the p53/SLC7A11/GPX4 axis in triple-negative breast cancer cells
Ming Lei, Yun-Long Zhang, Feng-Ying Huang, Heng-Yu Chen, Ming-Hui Chen, Ri-Hong Wu, Shu-Zhen Dai, Gui-Sheng He, Guang-Hong Tan, Wu-Ping Zheng · 2023
Read Gankyrin inhibits ferroptosis through the p53/SLC7A11/GPX4 axis in triple-negative breast cancer cells by Ming Lei, Yun-Long Zhang, Feng-Ying Huang, Heng-Yu Chen, Ming-Hui Chen, Ri-Hong Wu, Shu-Zhen Dai, Gui-Sheng He, Guang-Hong Tan, Wu-Ping Zheng (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10713534.txt.
Description
Ming Lei and co-authors show that a protein called gankyrin shields aggressive breast cancer cells from an iron-driven death, in a 2023 study. Triple-negative breast cancer lacks the usual drug targets and relapses often. Ferroptosis is a cell death driven by iron and fat damage. Forcing it could kill stubborn cancer cells.
Gankyrin runs high in these tumors and tracks with worse outlook. The team found it partners with a p53-destroying enzyme complex. With p53 degraded, a protective pathway stays open and ferroptosis is blocked. Blocking gankyrin restored the death route in cell tests. The chain offers several drug targets at once. Cancer biologists gain a clearer picture of how these cells survive.
Catalog record
| CREATOR | Ming Lei, Yun-Long Zhang, Feng-Ying Huang, Heng-Yu Chen, Ming-Hui Chen, Ri-Hong Wu, Shu-Zhen Dai, Gui-Sheng He, Guang-Hong Tan, Wu-Ping Zheng |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |